NEW YORK (GenomeWeb News) – Enzo Biochem's Enzo Clinical Labs division will market Ikonisys' OncoFISH cervical test, under an agreement announced today.
Enzo Clinical Labs will have exclusive marketing rights for the test in New York and New Jersey. It will offer the assay to doctors requesting advanced analysis of specimens from liquid-based Pap tests to assist them in evaluating cytologic reports. Ikonisys will conduct the evaluation of the specimen using its own CellOptics platform on the Ikoniscope Digital Microscopy System for interpreting molecular signals.
Enzo said that he assay is based on the identification of a genetic marker that has been linked with an increased likelihood for the development of cervical cancer.
In addition, the firm noted that the test already has received clearance in New York State.
"The results of Pap smears are not always conclusive," Kevin Krenitsky, president of Enzo Clinical Labs, said in a statement. "OncoFISH cervical provides an important new dimension for further evaluation, tied to chromosome related indicators, to determine the probability of progression to cervical cancer where the current results are indecisive or suspicious."
Terms of the pact were not disclosed.